Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelcuityFRA:7VR 30 12-1 Month Momentum % is 103.35% as of Aug. 16, 2026. GuruFocus rates FRA:7VR with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,354 Biotechnology companies, Celcuity ranks better than 89.81% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-16), Celcuity's 12-1 Month Momentum % is 103.35%.
The industry rank for Celcuity's 12-1 Month Momentum % or its related term are showing as below:
FRA:7VR's 12-1 Month Momentum % is ranked better than 89.81% of 1354
companies
in the Biotechnology industry
Industry Median: -18.41
vs FRA:7VR: 103.35
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Celcuity 12-1 Month Momentum % Related Terms
FRA:7VR vs RLAY, VKTX, DYN: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Celcuity's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celcuity 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celcuity's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Celcuity's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 103.35% mean?
Celcuity (FRA:7VR) has a 12-1 Month Momentum % of 103.35% as of Aug. 16, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #138 out of 1354 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Celcuity's 12-1 Month Momentum % too high?
Celcuity's current 12-1 Month Momentum % is 103.35%. Based on the distribution chart, Celcuity ranks #138 out of 1354 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celcuity has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's 12-1 Month Momentum % compare to RLAY and VKTX?
According to the Biotechnology industry distribution chart, Celcuity ranks #138 out of 1354 companies for 12-1 Month Momentum %. This places Celcuity in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Celcuity and its competitors. Celcuity's current 12-1 Month Momentum % is 103.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current 12-1 Month Momentum % of 103.35%. The current 12-1 Month Momentum % is 103.35%. Celcuity's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current 12-1 Month Momentum % is 103.35% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
30GF Score
Get the complete analysis for FRA:7VR
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VR has been successfully added to your 
